Developer docs
API playgroundTry for free, no card

Search company profiles

G Square

Full company profile

uuid0000fxb

Namestring
G Square
Legal namestring
G Square Healthcare Private Equity LLP
Company typeenum
Private
Founded yearint
2008
Descriptiontext

G Square Healthcare Private Equity LLP is a London-based private equity firm founded in 2008 by Dr. Laurent Ganem as the first European PE firm focused exclusively on healthcare investments. The firm invests across four healthcare sub-segments — Medical Products (equipment, devices, biomaterials), Healthcare IT (software, telehealth, AI, tech-enabled services), Healthcare Services (diagnostics, specialised clinics, social care), and Services to Pharma Industry (CROs, CDMOs) — deploying €30-50 million of equity per deal with a strong buy-and-build approach. The firm manages multiple fund vintages including G Square Capital II (€350M, 2017) and a €500M continuation vehicle (2022), with limited partners comprising North American and European institutional investors.

The firm's portfolio of approximately 25 platforms and 340 add-ons spans medical products (Serres surgical fluid management, G21 orthobiologics, Duomed MedTech distribution), digital health (Mayden with iaptus EHR used by 40,000+ NHS clinicians, ClinicLetter.ai ambient scribe, Portasana patient engagement, Medadom telehealth), healthcare services (Keys/Accomplish social care, Pharmacy2U online pharmacy, Argos veterinary clinics, Unicare Norway), and healthcare education (Healthcademia across 11 countries). The firm generates revenue through management fees on committed capital and performance-based carried interest on exits, and operates with FCA regulation (FRN 605527) and UN PRI signatory status since 2012.

The team of 32 professionals represents 17 nationalities and 400 years of combined healthcare investment experience, anchored by Founder/CEO Dr. Laurent Ganem (MD, Columbia MBA, ex-Baxter and Apax Partners) and supported by operating partners with deep NHS and healthcare executive backgrounds. G Square's go-to-market relies on proprietary deal sourcing through sector specialisation, direct outreach to healthcare entrepreneurs, and referral networks, with capital raised via private placement to institutional investors advised by Asante Capital and Proskauer.

Short descriptiontext

G Square Healthcare Private Equity LLP is a London-based private equity firm founded in 2008, investing €30-50M per deal across mid-market European healthcare platforms in Medical Products, Healthcare IT, Healthcare Services, and Pharma Services. The firm serves founders and management teams via buy-and-build strategies, funded by institutional LPs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, mid-market buyouts, growth capital investing, buy-and-build strategy, healthcare fund management
Industry2 codes
1Healthcare & Life Sciences Growth Equity
CodeFSANACABPrimaryYes
2Business Services (B2B) Growth Equity
CodeFSANACADPrimaryNo
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Private Equity / Private Equity Fund Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

G Square charges management fees on committed capital under management across its fund vehicles (G Square Capital I, II, III, IV, and continuation funds).

gsquarecapital.com
2Carried Interest
TypeTransaction Fee
Description

Performance-based carried interest from successful exits and realisation of portfolio companies, aligning GP and LP interests.

gsquarecapital.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

G Square Healthcare Private Equity LLP is a London-headquartered, FCA-authorised private equity firm that invests growth and buyout capital of €30–50 million per transaction in mid-market European healthcare companies. Its funds target four healthcare segments — Medical Products, Healthcare IT, Healthcare Services, and Services to the Pharma Industry — and pursue value creation primarily through buy-and-build strategies, deploying capital raised from institutional investors and earning revenue through management fees and carried interest on exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 25 deals completed across fund series
+2 more records
Product overview1 text field

G Square operates as a healthcare-focused private equity firm (G Square Healthcare Private Equity LLP) that invests in mid-market healthcare companies across Europe. The firm manages multiple funds and has portfolio companies spanning four healthcare segments: Medical Products, Healthcare IT, Healthcare Services, and Services to Pharma Industry. Key portfolio companies include Mayden (health tech with iaptus EHR system), Medadom (French telehealth), Serres (Finnish MedTech for surgical fluid management), Healthcademia (international healthcare education), G21 (Italian biomaterials for orthopaedics), Pharmacy2U (UK online pharmacy), and Keys Group (UK social care services). Mayden's product suite includes iaptus (EHR), Portasana (patient engagement platform), and ClinicLetter.ai (ambient voice technology for NHS). Additionally, G Square Group (a separate Indian real estate developer) develops plotted communities in Tamil Nadu including projects like Temple View Square and Seven Hills City.

Product and service3 records
1G Square Capital II Fund
CategoryPrivate Equity Fund / Healthcare Buyout Fund
Description

Closed-end healthcare-focused private equity fund of €350 million that invests growth and buyout capital of €30–50 million per deal in mid-market European healthcare companies across Medical Products, Healthcare IT, Healthcare Services and Services to Pharma Industry. Sold to institutional limited partners.

2G Square Capital Continuation Fund Vehicle
CategoryPrivate Equity Continuation Fund
Description

€500 million continuation fund vehicle that acquired three existing portfolio assets (Accomplish, Keys Group, and Denteam) from G Square Capital I and II, providing liquidity to certain investors and allowing new and existing LPs to participate in the next stage of growth of those assets.

3G Square Capital IV Fund
CategoryPrivate Equity Fund / Healthcare Buyout Fund
Description

Fourth-vintage healthcare-focused private equity fund of G Square, evidenced by its third investment in Mayden in November 2023. Deploys growth and buyout capital into mid-market European healthcare companies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Paree Group, the long-standing family owner of Serres, retained a significant stake when G Square acquired majority ownership. Paree Group continues as a strategic partner in Serres' next phase of development, leveraging G Square's healthcare expertise for international expansion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-16
Description

Duomed Group (G Square portfolio) executed put option agreement for contemplated sale to Palex Medical, creating a pan-European MedTech distribution platform spanning Northern, Western, and Southern Europe.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

European private equity firm with healthcare exposure that led G Square's €500M continuation vehicle in 2022. Operates a broader sector mandate but participates in mid- and upper mid-market healthcare transactions across Europe.

TypeDirect peer
Description

European technology and healthcare-focused private equity firm. Yasemin Arik joined G Square from Hg, and Hg has parallel sector mandates in healthcare software and tech-enabled services, making it a directly comparable peer for G Square's Healthcare IT vertical.

TypeDirect peer
Description

Pan-European healthcare-dedicated private equity firm headquartered in Lyon, France. Directly comparable to G Square as a healthcare specialist mid-market investor across medical products, services, and digital health with similar European geographic focus and equity check sizes.

TypeBroad incumbent
Description

Global private equity firm with a long-standing healthcare practice where G Square's founder Laurent Ganem worked from 1994. Operates a broader sector mandate but competes for European healthcare buyouts at similar mid-market scale.

TypeDirect peer
Description

European mid-market private equity firm with healthcare and consumer mandates. Loic Taieb joined G Square from CapVest, signaling directly comparable mid-market European healthcare deal sourcing.

TypeDirect peer
Description

Lower mid-market private equity arm of Rothschild & Co focused on software and healthcare. Oliver Hoenich joined G Square from Five Arrows, making it a directly comparable peer on deal size, sector focus, and European mid-market positioning.

TypeBroad incumbent
Description

European mid-market private equity firm with healthcare exposure. Emmanuel Amponsah worked at Bridgepoint before joining G Square, and Bridgepoint is a comparable competitor for mid-market European healthcare buyouts.

TypeBroad incumbent
Description

Global alternative asset manager with significant European mid-market healthcare exposure through its Strategic Equity and Partnership Capital strategies. Javier Serrano joined G Square from ICG, and ICG is a comparable source of competition for mid-cap healthcare buyouts.

TypeDirect peer
Description

Pan-European mid-market private equity firm with a dedicated healthcare vertical. Matteo Cefaliello joined G Square from Synova, indicating directly comparable deal sourcing, equity check sizes, and sector focus.

TypeBroad incumbent
Description

Global private markets investor that co-led G Square's €500M continuation vehicle with Eurazeo in 2022. Operates broader sector mandates but is a comparable LP and co-investor in European mid-market healthcare transactions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A11 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

G Square

Healthcare Private Equity / Private Equity Fund Managementgsquarecapital.com

G Square Healthcare Private Equity LLP is a London-based private equity firm founded in 2008, investing €30-50M per deal across mid-market European healthcare platforms in Medical Products, Healthcare IT, Healthcare Services, and Pharma Services. The firm serves founders and management teams via buy-and-build strategies, funded by institutional LPs.

What G Square does

G Square Healthcare Private Equity LLP is a London-based private equity firm founded in 2008 by Dr. Laurent Ganem as the first European PE firm focused exclusively on healthcare investments. The firm invests across four healthcare sub-segments — Medical Products (equipment, devices, biomaterials), Healthcare IT (software, telehealth, AI, tech-enabled services), Healthcare Services (diagnostics, specialised clinics, social care), and Services to Pharma Industry (CROs, CDMOs) — deploying €30-50 million of equity per deal with a strong buy-and-build approach. The firm manages multiple fund vintages including G Square Capital II (€350M, 2017) and a €500M continuation vehicle (2022), with limited partners comprising North American and European institutional investors.

The firm's portfolio of approximately 25 platforms and 340 add-ons spans medical products (Serres surgical fluid management, G21 orthobiologics, Duomed MedTech distribution), digital health (Mayden with iaptus EHR used by 40,000+ NHS clinicians, ClinicLetter.ai ambient scribe, Portasana patient engagement, Medadom telehealth), healthcare services (Keys/Accomplish social care, Pharmacy2U online pharmacy, Argos veterinary clinics, Unicare Norway), and healthcare education (Healthcademia across 11 countries). The firm generates revenue through management fees on committed capital and performance-based carried interest on exits, and operates with FCA regulation (FRN 605527) and UN PRI signatory status since 2012.

The team of 32 professionals represents 17 nationalities and 400 years of combined healthcare investment experience, anchored by Founder/CEO Dr. Laurent Ganem (MD, Columbia MBA, ex-Baxter and Apax Partners) and supported by operating partners with deep NHS and healthcare executive backgrounds. G Square's go-to-market relies on proprietary deal sourcing through sector specialisation, direct outreach to healthcare entrepreneurs, and referral networks, with capital raised via private placement to institutional investors advised by Asante Capital and Proskauer.

G Square firmographics

Firmographics
Name
G Square
Legal name
G Square Healthcare Private Equity LLP
Website
https://gsquarecapital.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
G Square Healthcare Private Equity LLP is a London-based private equity firm founded in 2008, investing €30-50M per deal across mid-market European healthcare platforms in Medical Products, Healthcare IT, Healthcare Services, and Pharma Services. The firm serves founders and management teams via buy-and-build strategies, funded by institutional LPs.
Ownership category
akta.pro rank

G Square industry classification

Industry
Product category
Healthcare Private Equity / Private Equity Fund Management
NAICS
Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282)
akta.pro primary industry
Healthcare & Life Sciences Growth Equity (FSANACAB)
akta.pro secondary industry
Business Services (B2B) Growth Equity (FSANACAD)

Keywords

  • Healthcare private equity
  • Mid-market buyouts
  • Growth capital investing
  • Buy-and-build strategy
  • Healthcare fund management

Where G Square is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

G Square business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Management Fees: G Square charges management fees on committed capital under management across its fund vehicles (G Square Capital I, II, III, IV, and continuation funds).
  2. Carried Interest: Performance-based carried interest from successful exits and realisation of portfolio companies, aligning GP and LP interests.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

G Square product offering

Product offering

Core offering

G Square Healthcare Private Equity LLP is a London-headquartered, FCA-authorised private equity firm that invests growth and buyout capital of €30–50 million per transaction in mid-market European healthcare companies. Its funds target four healthcare segments — Medical Products, Healthcare IT, Healthcare Services, and Services to the Pharma Industry — and pursue value creation primarily through buy-and-build strategies, deploying capital raised from institutional investors and earning revenue through management fees and carried interest on exits.

Product overview

G Square operates as a healthcare-focused private equity firm (G Square Healthcare Private Equity LLP) that invests in mid-market healthcare companies across Europe. The firm manages multiple funds and has portfolio companies spanning four healthcare segments: Medical Products, Healthcare IT, Healthcare Services, and Services to Pharma Industry. Key portfolio companies include Mayden (health tech with iaptus EHR system), Medadom (French telehealth), Serres (Finnish MedTech for surgical fluid management), Healthcademia (international healthcare education), G21 (Italian biomaterials for orthopaedics), Pharmacy2U (UK online pharmacy), and Keys Group (UK social care services). Mayden's product suite includes iaptus (EHR), Portasana (patient engagement platform), and ClinicLetter.ai (ambient voice technology for NHS). Additionally, G Square Group (a separate Indian real estate developer) develops plotted communities in Tamil Nadu including projects like Temple View Square and Seven Hills City.

Differentiator

Problem solved

Functional benefit

Products and services

  • G Square Capital II Fund Closed-end healthcare-focused private equity fund of €350 million that invests growth and buyout capital of €30–50 million per deal in mid-market European healthcare companies across Medical Products, Healthcare IT, Healthcare Services and Services to Pharma Industry. Sold to institutional limited partners.
  • G Square Capital Continuation Fund Vehicle €500 million continuation fund vehicle that acquired three existing portfolio assets (Accomplish, Keys Group, and Denteam) from G Square Capital I and II, providing liquidity to certain investors and allowing new and existing LPs to participate in the next stage of growth of those assets.
  • G Square Capital IV Fund Fourth-vintage healthcare-focused private equity fund of G Square, evidenced by its third investment in Mayden in November 2023. Deploys growth and buyout capital into mid-market European healthcare companies.

Quantifiable outcome

  • 25 deals completed across fund series
  • +2 more outcomes

Companies that use G Square

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

G Square technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

G Square partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Paree GroupcoreStrategic or Co-development Partner · 20 January 2026Paree Group, the long-standing family owner of Serres, retained a significant stake when G Square acquired majority ownership. Paree Group continues as a strategic partner in Serres' next phase of development, leveraging G Square's healthcare expertise for international expansion.
  • Palex MedicalcoreStrategic or Co-development Partner · 16 April 2024Duomed Group (G Square portfolio) executed put option agreement for contemplated sale to Palex Medical, creating a pan-European MedTech distribution platform spanning Northern, Western, and Southern Europe.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

G Square competitors and assessment

Company assessment

Broad incumbents

  • Eurazeo: European private equity firm with healthcare exposure that led G Square's €500M continuation vehicle in 2022. Operates a broader sector mandate but participates in mid- and upper mid-market healthcare transactions across Europe.
  • Apax Partners: Global private equity firm with a long-standing healthcare practice where G Square's founder Laurent Ganem worked from 1994. Operates a broader sector mandate but competes for European healthcare buyouts at similar mid-market scale.
  • Bridgepoint Group: European mid-market private equity firm with healthcare exposure. Emmanuel Amponsah worked at Bridgepoint before joining G Square, and Bridgepoint is a comparable competitor for mid-market European healthcare buyouts.
  • Intermediate Capital Group (ICG): Global alternative asset manager with significant European mid-market healthcare exposure through its Strategic Equity and Partnership Capital strategies. Javier Serrano joined G Square from ICG, and ICG is a comparable source of competition for mid-cap healthcare buyouts.
  • Schroders Capital: Global private markets investor that co-led G Square's €500M continuation vehicle with Eurazeo in 2022. Operates broader sector mandates but is a comparable LP and co-investor in European mid-market healthcare transactions.

Direct peers

  • Hg (Hg Capital): European technology and healthcare-focused private equity firm. Yasemin Arik joined G Square from Hg, and Hg has parallel sector mandates in healthcare software and tech-enabled services, making it a directly comparable peer for G Square's Healthcare IT vertical.
  • ARCHIMED: Pan-European healthcare-dedicated private equity firm headquartered in Lyon, France. Directly comparable to G Square as a healthcare specialist mid-market investor across medical products, services, and digital health with similar European geographic focus and equity check sizes.
  • CapVest Partners: European mid-market private equity firm with healthcare and consumer mandates. Loic Taieb joined G Square from CapVest, signaling directly comparable mid-market European healthcare deal sourcing.
  • Five Arrows Capital Partners (Rothschild): Lower mid-market private equity arm of Rothschild & Co focused on software and healthcare. Oliver Hoenich joined G Square from Five Arrows, making it a directly comparable peer on deal size, sector focus, and European mid-market positioning.
  • Synova Capital: Pan-European mid-market private equity firm with a dedicated healthcare vertical. Matteo Cefaliello joined G Square from Synova, indicating directly comparable deal sourcing, equity check sizes, and sector focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

G Square social profiles

Digital presence

G Square compliance and trust

Trust signal

Compliance4 records

G Square financial estimates

Financial estimate

Revenue estimate

Valuation estimate

G Square leadership team

Management profile

Number of profiles

Profiles7 records

G Square funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

G Square M&A and investment

M&A and investment

M&A11 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about G Square

What does G Square do?

G Square Healthcare Private Equity LLP is a London-headquartered, FCA-authorised private equity firm that invests growth and buyout capital of €30–50 million per transaction in mid-market European healthcare companies. Its funds target four healthcare segments — Medical Products, Healthcare IT, Healthcare Services, and Services to the Pharma Industry — and pursue value creation primarily through buy-and-build strategies, deploying capital raised from institutional investors and earning revenue through management fees and carried interest on exits.

Is G Square a public or private company?

G Square is a private company. It is classified as management employee owned and is currently operating.

When was G Square founded?

G Square was founded in 2008. It employs 11 to 50 people.

Where is G Square based?

G Square is headquartered in London, United Kingdom, in the Europe region.

How does G Square make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are G Square's main competitors?

Broad incumbents on record are Eurazeo, Apax Partners, Bridgepoint Group, Intermediate Capital Group (ICG) and Schroders Capital. Direct peers are Hg (Hg Capital), ARCHIMED, CapVest Partners, Five Arrows Capital Partners (Rothschild) and Synova Capital.

Does G Square have an API?

No public API is recorded for G Square.

What industry is G Square in?

G Square's product category is Healthcare Private Equity / Private Equity Fund Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANACAD, Business Services (B2B) Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestorsinhealthcareItaly: G Square acquires majority stake in ValtecneG Square acquired an 82% stake in Italian orthopaedic components maker Valtecne from the Mainetti family for €72.5m, with a planned mandatory tender offer at €11.87 per share. The deal, financed partly by cash and debt, aims to accelerate growth and pursue selective acquisitions.InvestorsinhealthcareUK: G Square Healthcare PE closes £500m single-asset continuation fund for Pharmacy2UG Square Healthcare PE closed a £500m (US$668m) single-asset continuation fund for Pharmacy2U, the UK's largest online pharmacy. The fund provides liquidity to existing limited partners and is expected to be completed in the coming weeks.InvestorsinhealthcareItaly: G Square acquires majority shareholding in Valtecne with view to delistingG Square, a healthcare investment firm, is acquiring approximately 82% of Valtecne, an Italy-based listed contract manufacturer of high-precision mechanical components. The acquisition is intended to delist Valtecne from the stock exchange.BeBeezG Square acquisisce l'82% di Valtecne dalla famiglia Mainetti per 72,5 mln euro e annuncia opa a 11,87 euro per il delisting dall'EGM - BeBeezG Square Healthcare Private Equity, a London-based European healthcare-focused mid-market fund, has signed a binding agreement to acquire approximately 82% of Valtecne spa at an equity value of 72.5 million euros, corresponding to 11.87 euros per share. Valtecne is a Valtellinese precision mechanics company serving the MedTech sector, previously controlled by the Mainetti family and listed on Euronext Growth Milan since March 2023, when it debuted at 5 euros per share. As part of the transaction, G Square has announced a public tender offer (OPA) at the same price to delist the company from the EGM market.Business StandardG Square acquires TVS founder's legacy land in Madurai for ₹300 croreG Square Group has acquired a five-acre heritage land parcel in central Madurai from the TVS Group for ₹300 crore, in what is described as one of the city's most significant real estate transactions in recent years. The land was formerly owned by the late T V Sundaram Iyengar, founder of the TVS Group, and is believed to be the group's original landholding, lending the property considerable historical importance. G Square Group will develop the site as a premium plotted community called G Square Temple View Square (TVS), offering 55 plots priced from ₹15,990 per sq. ft. for residential and ₹25,990 per sq. ft. for commercial units.BusinessLineG Square acquires heritage land in Madurai, launches Temple View Square projectG Square Group, a Chennai-based real estate company, has acquired a five-acre heritage land parcel in Madurai from the legacy owners of the TVS Group for a total land value of ₹300 crore. The site, once owned by TV Sundaram Iyengar, founder of the TVS Family Group, is G Square’s first landholding with historical significance. The company has launched G Square Temple View Square (TVS), a premium plotted development comprising 50 residential and 5 commercial plots on 1.63 acres and 2 acres respectively, with residential pricing starting at ₹15,990 per sq. ft.PR NewswireG Square acquires majority stake in Finnish MedTech company Serres to accelerate global growth and sustainability leadershipG Square, a European healthcare private equity investor, has signed an agreement to acquire a majority stake in Finnish MedTech company Serres, which specializes in sustainable surgical fluid management solutions, with the transaction expected to close in Q1 2026. Paree Group, the long-standing family owner, will retain a significant stake and continue as a strategic partner in Serres' next phase of development. G Square plans to accelerate Serres' international expansion, particularly in the United States, invest in new products and commercial capabilities, and pursue targeted acquisitions to build Serres into a leading global MedTech platform.PR NewswireG Square acquires majority stake in Finnish MedTech company Serres to accelerate global growth and sustainability leadershipG Square, a European healthcare private equity firm, has signed an agreement to acquire a majority stake in Finnish MedTech company Serres, which specializes in sustainable surgical fluid management solutions. Paree Group, the long-standing family owner, will retain a significant stake and continue as a strategic partner as Serres seeks to accelerate its global expansion, particularly in the United States. The transaction, expected to close in the first quarter of 2026, positions Serres to build on its leading position in Europe through investments in new products, commercial capabilities, and targeted acquisitions.SerresG Square Acquires Majority Stake in SerresG Square, a European healthcare private equity investor, has signed an agreement to acquire a majority stake in Serres, a Finnish MedTech company specializing in sustainable surgical fluid management solutions for surgery and intensive care. Paree Group, the long-standing family owner, will retain a significant stake and continue as a strategic partner while G Square brings healthcare expertise and financial resources to accelerate Serres' global expansion, particularly in the United States. The transaction is expected to close in the first quarter of 2026, with plans to develop Serres into a leading international MedTech platform through investments in new products, commercial capabilities, and targeted acquisitions.Pulse 2.0G Square Takes Majority Stake In Serres To Back Global Expansion Of Sustainable Surgical Fluid ManagementG Square has agreed to acquire a majority stake in Serres, a Finnish MedTech company specializing in surgical fluid management and suction solutions, with the transaction expected to close in Q1 2026. Paree Group, the long-standing family owner, will retain a significant minority stake and continue as a strategic partner. The new ownership structure is designed to accelerate Serres' international growth, particularly in the United States, while building on its sustainability-focused product strategy and circularity efforts in single-use medical solutions.